Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth


Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):


Middle area:

Key facts & figures

Sanofi is an integrated global healthcare company focused on patient needs. Our business includes pharmaceuticals (prescription drugs, consumer healthcare and generics), vaccines and animal health.

The creation of growth platforms and the evolution of our R&D pipeline have effectively transformed Sanofi into a major biopharmaceutical player.

FY 2014 Net Sales


+4.9% at constant exchange rates
+2.5% on a reported basis


FY 2014 Business EPS


+7.3% at constant exchange rates
+3.0% on a reported basis


Growth Platforms in 2014


+10.7% at constant exchange rates
Accounted for 76.4% of total sales in 2014


Emerging Markets: Sanofi is the #1 healthcare company in Emerging Markets with a broad product portfolio adapted to local needs.

Diabetes Solutions: Lantus®, our basal insulin, is the world’s leading diabetes brand.

Human Vaccines: Sanofi Pasteur offers a broad range of vaccines against 20 serious diseases and is the undisputed leader in flu vaccines.

Consumer Healthcare (CHC): Sanofi is the world's 3rd largest CHC player.

Genzyme: a leader in biotechnology, is our global center for excellence in rare diseases and multiple sclerosis.

Animal Health: Merial is a global leader in Animal Health with expertise in both veterinary pharmaceutical products and vaccines.

Other Innovative Products: On February 5, 2015, the R&D portfolio included 43 projects, 14 of which were in Phase III or had been submitted for approval.

Sales of Growth Platforms in 2014
FY 2014 salesGrowth at CER
Emerging Markets*€11,347m+9.3%
Diabetes Solutions€7,273m+12.1%
Consumer Healthcare**€3,337m+16.5%
Animal Health€2,076m+6.7%
Other Innovative Products***€815m+14.7%

* Excluding Generics in Brazil, Emerging Markets grew +6.5% in FY 2014 at CER
**Some products recorded in prescription pharmaceuticals in 2013 were transferred as Consumer Healthcare products and totaled €273m in FY 2013. When excluding this category change, sales of Consumer Healthcare grew +6.8% in FY 2014 at CER
Products launched since 2009 which are not included in the Growth Platforms listed above: Multaq®, Jevtana®, Auvi-Q™, Mozobil® and Zaltrap®


Right area:

Stock Market

IR mobile application

SANOFI IR - The Investor Relations Mobile Application

SANOFI IR is available on iPhone, iPad and Android!


Regeneron Alliance



New interpretation of tax levies - applicable as from January 1st, 2014



Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013


© Sanofi 2004-2015 - All rights reserved - Update: April 14, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)